Document is current
Any future updates will be listed below
-
Authors
Sato, Sakura https://orcid.org/0000-0003-3674-0759
Nagakura, Ken-ichi https://orcid.org/0000-0002-9381-9044
Yanagida, Noriyuki https://orcid.org/0000-0001-9643-744X
Ebisawa, Motohiro https://orcid.org/0000-0003-4117-558X
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 29 September 2025
First Online: 15 October 2025
Declarations
:
: Motohiro Ebisawa has received consulting fees from Novartis, Sanofi, ARS-Pharmaceuticals, and honoraria from Viatris. The other authors have no conflict of interest to declare.
